Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released May 6, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001193125-26-209731
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $268.06M | $244.32M | $205.83M | $118.46M |
| Net Income | $3.64M | $18.99M | $16.56M | -$43.02M |
| EPS Diluted |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| $0.02 |
| $0.11 |
| $0.10 |
| -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
